Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | PIR | O00625 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.47 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | STK16 | O75716 | 1/20 | 0.47 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16506281 | 0.92 | BRAF (0.52) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 | |
| SCHEMBL14716140 | 0.92 | BRAF (0.52) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 | |
| Uplarafenib SCHEMBL14716189 | 0.92 | BRAF (0.51) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 | |
| Uplarafenib SCHEMBL29623930 | 0.92 | BRAF (0.51) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 | |
| SCHEMBL14716344 | 0.90 | CYP2C19 (0.52) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 | |
| SCHEMBL14716024 | 0.88 | BRAF (0.48) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 | |
| SCHEMBL16506339 | 0.88 | BRAF (0.47) | BRAFCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL14809513 | 0.87 | BRAF (0.46) | BRAFCYP2C19CYP2C9 | |
| SCHEMBL14716235 | 0.85 | BRAF (0.46) | BRAF | |
| SCHEMBL14716257 | 0.85 | BRAF (0.57) | BRAFCYP2C19CYP2C9CYP3A4MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | claimed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | claimed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9295671-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2016-03-29 | — | — | US | claimed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | claimed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2747767-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | NEUPHARMA, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20150057276-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2757885-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043935-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043935-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | BRAF 2/4885CYP2C19 946/4885CYP2C9 695/4885 |
| US-10561652-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, BRAF, CHEK1 | BRAF 2/4885CYP2C19 946/4885CYP2C9 695/4885 |
| US-20150057276-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | BRAF 1/4885CYP2C19 1047/4885CYP2C9 1506/4885 |
| US-10137125-B2 | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer | PDXK, CHEK1, CHEK2 | BRAF 4/4885CYP2C19 948/4885CYP2C9 702/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | BRAF 1/4885CYP2C19 1087/4885CYP2C9 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.